Purpose of Review: Throughout the field of oncology, immunotherapy is moving further towards the first-line setting, and there is encouraging data for the use of these novel therapies in the management of lymphomas, utilizing treatments approved for both solid and hematologic malignancies. Herein, we review promising advances in this rapidly moving field from the past year. Recent Findings: In the last year, we have seen promising clinical data on engineered antibody therapies for the treatment of lymphomas, as well as further optimization of engineered antibody fragments fused onto linkers or chimeric T cell receptors, both of the modalities capable of transforming non-specific T cells into tumor-specific, serial killer cells. Summary: Here we will review the promising data on these advances in antibody-based therapies, as well as some of the immunomodulators and checkpoint-blocking therapies that shown to have promising results in the treatment of lymphomas within the past year.

Original languageEnglish
Pages (from-to)282-289
Number of pages8
JournalCurrent Hematologic Malignancy Reports
Issue number4
StatePublished - 1 Aug 2017


  • Lymphoma immunotherapy


Dive into the research topics of 'An Update on the Use of Immunotherapy in the Treatment of Lymphoma'. Together they form a unique fingerprint.

Cite this